Examining the Biotech 2017 Landscape: Trump, IPOs, Alternative Approvals Pathways, and More
Original article posted on the PM360
Earlier this month, San Francisco once again played host to thousands of investors who wanted to take the pulse of the biotech industry for 2017 and to see if they can find the most worthy companies or areas deserving of investment. Yes, the 35th Annual J.P. Morgan Healthcare Conference came and went—as did the rival 9th Annual Biotech Showcase held just down the street—so now it’s time to reflect on what those investors learned.
PM360 spoke to Nate Gallon, Partner at Hogan Lovells LLP in Silicon Valley, as well as his colleague Asher Rubin, Global Head of the Life Sciences Industry Group at Hogan Lovells LLP, who were present at both conferences and spoke to plenty of attendees. Additionally, Rubin also moderated a panel at the Biotech Showcase on “Partnership and Alliance Models with Tech, Pharma, and Medical Devices,” which featured speakers from Qualcomm Life, Johnson & Johnson Health and Wellness Solutions, Verily Life Sciences, and Proteus Digital Health. Together they share their perspectives on the conferences, what themes emerged, what company presentations interested them the most, how the industry plans to handle Trump, and much more.